Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
2(18%)
Results Posted
0%(0 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_4
1
9%
Ph phase_2
3
27%
Ph phase_3
2
18%
Ph phase_1
2
18%
Ph early_phase_1
1
9%

Phase Distribution

3

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
2(22.2%)
Phase 4Post-market surveillance
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

11

all time

Status Distribution
Active(2)
Completed(6)
Terminated(1)
Other(2)

Detailed Status

Completed6
unknown2
Recruiting1
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
2
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (11.1%)
Phase 12 (22.2%)
Phase 23 (33.3%)
Phase 32 (22.2%)
Phase 41 (11.1%)

Trials by Status

recruiting19%
terminated19%
completed655%
unknown218%
active_not_recruiting19%

Recent Activity

2 active trials
Showing 5 of 11
recruitingphase_2

Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer

NCT05709574
completedphase_2

Effect of PDE5 Inhibition on Adipose Metabolism in Humans

NCT04684589
completedphase_1

A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil

NCT04540744
completedphase_1

A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants

NCT05236231
active_not_recruitingphase_2

Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial

NCT05173896
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05709574Phase 2

Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer

Recruiting
NCT04684589Phase 2

Effect of PDE5 Inhibition on Adipose Metabolism in Humans

Completed
NCT04540744Phase 1

A Study of Macitentan/Tadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil

Completed
NCT05236231Phase 1

A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants

Completed
NCT05173896Phase 2

Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial

Active Not Recruiting
NCT03049540Phase 3

Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function

Completed
NCT04164355

Study of Retinal and Choriocapillary Vascular Changes in Patients Undergoing Tadalafil 20mg

Completed
NCT04491773

Study of Retinal and Choriocapillary Vascular Changes in Patients Undergoing Tadalafil 20mg for More Than 6 Months

Completed
NCT02653833Early Phase 1

The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy

Terminated
NCT03905018Phase 3

Effect of Tadalafil Administration on Vasodilatation Mediated by Flow in Patients With Obesity Grade I-II

Unknown
NCT01364701Phase 4

Evaluation of Safety and Effectiveness of 2 Lower Dose Combined PDE5i's Versus Single Maximal Dose PDE5i Treatment

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11